Griffon Corporation Schedules Conference Call To Discuss Third Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)-- Griffon Corporation (“Griffon” or the “Company”) (NYSE: GFF) today announced it will release the Company’s fiscal third quarter results on Wednesday, August 5, 2026, followed by a conference call at 8:30 AM ET.

The call can be accessed by dialing 1-844-826-3035 (U.S. participants) or 1-412-317-5195 (International participants). Callers should ask to be connected to the Griffon Corporation teleconference or provide conference ID number 10210214. Participants are encouraged to dial-in at least 10 minutes before the scheduled start time.

A replay of the call will be available starting on Wednesday, August 5, 2026, at 11:30 AM ET by dialing 1-844-512-2921 (U.S.) or 1-412-317-6671 (International) and entering the conference ID number: 10210214. The replay will be available through Wednesday, August 19, 2026, at 11:59 PM ET.

About Griffon Corporation

Griffon is a leading provider of residential and commercial building products. The Company is the largest North American manufacturer and marketer of garage doors under the Clopay, IDEAL and Holmes brands, and rolling steel door and grille products under the Clopay, Cornell, and Cookson brands. The Company is also a leading provider of residential, industrial, and commercial ceiling fans sold under the Hunter, Casablanca, and Jan Fan brands.

The AMES North America, Australia, and United Kingdom businesses are classified as discontinued operations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729469231/en/

Company Contact:
Brian G. Harris
EVP & Chief Financial Officer
Griffon Corporation
(212) 957-5000

Investor Relations Contact:
Tom Cook
Managing Director
ICR Inc.
(203) 682-8250

Source: Griffon Corporation

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Freeport-McMoRan shares surge as copper hits record $14,694/ton
• BrYet Announces AIFA Approval of First-In-Kind cGMP Manufacturing Line for ML-016, Enabling Imminent Clinical Supply to Australia